Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eucarbon is a traditional, natural intestinal regulator and mild laxative originally developed in 1909 by the Austrian pharmaceutical company F. Trenka. It is formulated as a combination of non-activated vegetable charcoal, senna leaves, rhubarb root extract, and purified sulfur. The drug exerts a dual mechanism of action: the vegetable charcoal acts as an adsorbent to bind gases, toxins, and bacterial byproducts in the intestine, while the anthraquinone glycosides (sennosides) from senna and rhubarb stimulate intestinal peristalsis and promote water secretion into the lumen to facilitate bowel evacuation. Purified sulfur provides a mild disinfectant effect in the gastrointestinal tract. Eucarbon is primarily indicated for the treatment of constipation, abdominal bloating, flatulence, and irritable bowel syndrome (IBS). In some markets, such as Italy, Giuliani Pharma distributes updated formulations (like Eucarbon R.I.) that replace senna, rhubarb, and sulfur with ginger and dandelion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Eucarbon.